- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02440867
Treating Social Cognition With Theta Burst Stimulation; a Pilot Sudy (PilotTMS-COG)
Treating Social Cognition Impairments in Patients With Schizophrenia With Repetitive Transcranial Magnetic Stimulation (Theta-Burst; TBS); a Pilot Study
Study Overview
Status
Intervention / Treatment
Detailed Description
The language understanding of other people is based on linguistic decoding mechanisms (phonological, semantic, syntactic ...) but also more on subtle mechanisms for the recognition of emotions and intentions. Interact with another one requires understanding its language but also to infer emotions and intentions. There are patients with schizophrenia suffering from social cognition disorders that impair social interactions; These patients often have difficulty in extracting the non-verbal emotional content of language and have difficulty inferring the thoughts and intentions of others. Recently, we have suggested a link between such deficits and the hypofunction of the medial prefrontal cortex.
Transcranial magnetic stimulation is a noninvasive neuromodulation technique that increases or decreases the focal cortical excitability depending on stimulation parameters. This technique is now commonly used as a therapeutic tool. It has been tried with some success in patients with schizophrenia in some indications:
- To reduce the auditory verbal hallucinations stimulating the temporal cortex
- More rarely, to reduce the negative symptoms stimulating the dorsolateral prefrontal cortex So far, the medial prefrontal cortex was not considered as a possible target as the scalp to cortex distance prevent from using conventional stimulation coils. Recently new coils have been developed that permit stimulation of deeper cortical regions.
We hypothesize that the use of transcranial magnetic stimulation with a theta burst intermittent protocol known to increase the cortical excitability and aiming the medial prefrontal cortex with a special antenna will improve social interaction capabilities of schizophrenic patients.
This ambitious and innovative assumption shall be first supported by a study of feasibility which is the subject of this trial.
Moreover, changes in the anatomical and functional connectivity, in brain metabolism and in cortical excitability will be observed after stimulation thanks to a multimodal imaging and the study of P50 wave.
In this pilot study, involving 20 patients, we plan to assess the social cognition deficits before and after 10 sessions of magnetic stimulation (2 sessions per day for 5 consecutive days) using a neuronavigation system and Magstim® stimulator. In order to assess the feasibility and specificity of the stimulation of medial prefrontal cortex (MPC), the effects of this treatment will be compared to the effects of the same treatment aiming the dorsolateral prefrontal cortex (DLPFC), also involved in aspects of negative symptoms of schizophrenia, and placebo effects induced by sham stimulation (using a sham coil). The recording of the P50 wave will be just before and after the 1st session and just after the last stimulation session. An MRI anatomical, functional and spectroscopic be performed before and 30 days after the treatment. A control group of twenty healthy subjects will perform the same MRI acquisitions.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Clement Nathou, MD
- Phone Number: +33 (0)231065018
- Email: nathou@chu-caen.fr
Study Contact Backup
- Name: Sonia Dollfus, MD, PhD
- Phone Number: +33 (0)231065018
- Email: dollfus@chu-caen.fr
Study Locations
-
-
-
Caen, France, 14033
- Recruiting
- CHU de Caen - Centre Esquirol
-
Contact:
- Clément Nathou, Dr.
- Phone Number: +33231065018
- Email: nathou-c@chu-caen.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- with a diagnosis of schizophrenia or schizoaffective disorder (DSM-IV MINI R)
- less than 20 years of disease duration
- Having signed a written informed consent
- LIS score > 15 or negative PANSS score > 15
Exclusion Criteria:
- Any change in psychotropic drugs (antidepressants, antipsychotics or mood stabilizers) during the two months preceding the inclusion
- Pregnant or breastfeeding women
- Subjects with a neurological condition or with epilepsy
- Subjects with a counter-indication to MRI or Transcranial stimulation (electronic or metal implants)
- Subjects that refuse to wear earplugs during MRI
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Healthy subjects
Multimodal imaging data acquisitions Clinical data acquisitions
|
|
Experimental: TBS-MPC
|
Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
|
Active Comparator: TBS-CPDLF
|
Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
|
Sham Comparator: TBS-Sham
|
Sham stimulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
V-LIS total score
Time Frame: change from baseline in V-LIS total score compared to 30 days after the end of the treatment
|
change from baseline in V-LIS total score compared to 30 days after the end of the treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GLX ratio
Time Frame: change in baseline GLX ratio measured in MRSI compared to 30 days after the end of the treatment
|
GLX (= Glutamine + Glutamate) ratio are measured in the DLPFC and in the MPC
|
change in baseline GLX ratio measured in MRSI compared to 30 days after the end of the treatment
|
P50 wave amplitude
Time Frame: change in baseline P50 amplitude compared to immediately after the end of the treatment
|
change in baseline P50 amplitude compared to immediately after the end of the treatment
|
|
Motor activity
Time Frame: change in baseline motor activity measured with an actimeter compared to 30 days after the end of the treatment
|
change in baseline motor activity measured with an actimeter compared to 30 days after the end of the treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Clément Nathou, MD, University Hospital, Caen
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-A00839-38
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Social Cognition in Patients With Schizophrenia
-
University Hospital, CaenUniversity Hospital, Rouen; Centre Hospitalier Universitaire Dijon; Poitiers...RecruitingSocial Cognition in Patients With SchizophreniaFrance
-
Assistance Publique - Hôpitaux de ParisRecruitingSocial Cognition of Schizophrenia, Bipolas or Depressed PatientsFrance
-
University of Maryland, BaltimoreNational Institute on Drug Abuse (NIDA)CompletedSocial Anxiety | Social Cognition | Emotional IntelligenceUnited States
-
University of La LagunaUniversity of Santiago de CompostelaCompletedSocial CognitionSpain
-
Oslo University HospitalCompleted
-
University of California, San FranciscoSan Francisco Veterans Affairs Medical CenterCompleted
-
Mansoura UniversityRecruitingNocturnal Polyurea in Patients With BPHEgypt
-
Sumitomo Pharma (Suzhou) Co., Ltd.TerminatedFirst Episode Schizophrenia | Social Function | Cognition Function | BlonanserinChina
-
University of California, San FranciscoSan Francisco Veterans Affairs Medical CenterCompletedPsychotic Disorders | Schizophrenia | Oxytocin | Social CognitionUnited States
-
University of California, San FranciscoCompletedSchizophrenia | Oxytocin | Social Cognition | Magnetoencephalography (MEG)United States
Clinical Trials on Active TBS
-
Chang Gung Memorial HospitalEnrolling by invitationSuspected Non-Alzheimer Disease Pathophysiology (SNAP)Taiwan
-
Stanford UniversityRecruitingTreatment Resistant DepressionUnited States
-
Stanford UniversityRecruitingTreatment Resistant DepressionUnited States
-
Stanford UniversityRecruiting
-
QualissimaPharmacog's project (IMI)Terminated
-
Stanford UniversityNot yet recruitingTreatment Resistant DepressionUnited States
-
Stanford UniversityCompletedTreatment Resistant DepressionUnited States
-
University Hospital, CaenUniversity Hospital, Rouen; Centre Hospitalier Universitaire Dijon; Poitiers...RecruitingSocial Cognition in Patients With SchizophreniaFrance
-
University of Sao PauloUnknownDepressive Disorder | Bipolar Disorder | Depressive EpisodeBrazil
-
University of Sao PauloActive, not recruitingBipolar Disorder, Type 1Brazil